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OBJECTIVES The study evaluated the efficacy and safety of a short-acting reduced-dose fibrinolytic regimen
to promote early infarct-related artery (IRA) patency during the inherent delay experienced
by infarct patients referred for angioplasty as the principal recanalization modality.
BACKGROUND Previous approaches using long-acting, full-dose thrombolytic infusions rarely showed
benefit, but they did increase adverse event rates.
METHODS Following aspirin and heparin, 606 patients were randomized to a 50-mg bolus of
recombinant tissue-type plasminogen activator (rt-PA) (alpha half-life 4.5 min) or to placebo
followed by immediate angiography with angioplasty if needed. The end points included patency
rates on catheterization laboratory (cath lab) arrival, technical results when PTCA (percutaneous
transluminal coronary angioplasty) was performed, complication rates, and left ventricular (LV)
function by treatment assignment and time to restored patency following angioplasty.
RESULTS Patency on cath lab arrival was 61% with rt-PA (28% Thrombolysis in Myocardial Infarction
trial [TIMI]-2, 33% TIMI-3), and 34% with placebo (19% TIMI-2, 15% TIMI-3) (p 5
0.001). Rescue and primary PTCA restored TIMI-3 in closed arteries equally (77%, 79%).
No differences were observed in stroke or major bleeding. Left ventricular function was similar in
both treatment groups, but convalescent ejection fraction (EF) was highest with a patent IRA
(TIMI-3) on cath lab arrival (62.4%) or when produced by angioplasty within an hour of bolus
(62.5%). However, in 88% of angioplasties, the delay exceeded 1 h: convalescent EF 57.3%.
CONCLUSIONS Tailored thrombolytic regimens compatible with subsequent interventions lead to more
frequent early recanalization (before cath arrival), which facilitates greater LV function
preservation with no augmentation of adverse events. (J Am Coll Cardiol 1999;34:1954–62)
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The recent literature regarding management of acute myo-
cardial infarction (AMI) has emphasized the choice be-
tween intravenous (IV) fibrinolytic therapy and primary
angioplasty (1–5). An alternative might be a strategy
combining both approaches. The first goal of such a
combination would be to overcome the only modest
reperfusion success rates with thrombolytics by the im-
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mediate application of early rescue angioplasty for drug
failures. The second goal would be to blunt the negative
impact of frequent long delays in performing primary
angioplasty by producing, in some patients, very early
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recanalization accomplished by initial thrombolytic use.
Such a combination strategy, however, is generally believed
to lessen the technical success rate of primary angioplasty
and result in excess bleeding; thus, the two are thought not
to be compatible.
This noncompatibility notion had its origin in a small
comparative trial of primary angioplasty versus thrombolysis
plus immediate angioplasty, which enrolled only 121 pa-
tients (6) but documented an unacceptably high complica-
tion rate. The notion was indirectly enhanced by larger
studies (7–12) showing no advantage for an “aggressive”
regimen (angiography and often angioplasty after throm-
bolysis) over a less complicated course in conservatively
managed postthrombolysis patients. In these latter trials,
however, percutaneous transluminal coronary angioplasty
(PTCA) if performed early (and most commonly on already
patent vessels) was undertaken during the thrombolytic
infusion, which potentially contributed to the higher re-
ported rates of bleeding compared with patients assigned to
a noninterventional strategy. No large trial has directly
compared primary angioplasty to a strategy utilizing a very
short-acting and reduced-dose thrombolytic followed by
immediate angiography plus planned rescue angioplasty (as
necessary for occluded infarct-related arteries [IRAs]).
The current trial was therefore conducted to interrogate
several hypotheses: 1) that patients receiving a reduced bolus
dose of recombinant tissue-type plasminogen activator (rt-
PA) would show an increased rate of very early IRA patency
compared with those who received a placebo bolus; 2) that
such rapidly reperfused patients would demonstrate greater
preservation of convalescent left ventricular (LV) function than
those who required mechanical recanalization; 3) that the short
half-life thrombolytic would not negatively influence the tech-
nical outcome of angioplasty when required; and 4) that there
would not be an increase in reocclusion or clinical adverse
events for rt-PA patients versus placebo patients.
METHODS
Patient population. The Plasminogen-activator Angio-
plasty Compatibility Trial (PACT) was a multicenter,
randomized, double-blind, placebo-controlled study in
AMI patients. Patient eligibility criteria included isch-
emic symptoms $30 min and ST-segment elevation
$0.1 mV in $2 limb leads or $0.2 mV in $2 contiguous
precordial leads. Exclusions were age .75, prior cerebro-
vascular accident or transient ischemic attack, head
trauma within six months, active bleeding or bleeding
diathesis, recent trauma or major surgery, prior bypass surgery,
PTCA within six months, AMI symptoms .6 h, systolic
blood pressure .170 or diastolic .110 mm Hg at random-
ization. Pregnant or lactating women were also excluded. The
protocol was approved by each institution’s Review Board or
Ethical Committee. All patients gave written informed con-
sent. Oversight was provided by an independent Data Safety
and Monitoring Committee (Appendix A).
Study protocol. The double-blinded study design is depicted
in Figure 1. Eligible patients received unfractionated heparin,
a 5,000-IU bolus followed by an infusion of 1,000 IU/h
(1200 IU/h for patients .80 kg) and 325 mg of aspirin
(chewed and swallowed). Randomization was to an IV bolus of
rt-PA 50 mg (Activase, Genentech; Actilyse, Boehringer-
Ingelheim, GmbH) given over 3 min or an IV placebo bolus
given in an identical manner. Randomization (arranged in
blocks by institution) was accomplished by selecting sealed
study drug kits in prespecified sequential order.
Patients were to undergo angiography as soon as
possible following study drug. On cath lab arrival, the
initial injection of the IRA was used to assess patency as
described in the Thrombolysis in Myocardial Infarction
(TIMI) trial (13). If the IRA was occluded (TIMI flow
grade 0 or 1) or open but with sluggish flow (TIMI flow
grade 2), immediate angioplasty was performed (termed
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
aPTT 5 activated partial thromboplasin times
Cath lab 5 catheter laboratory
EF 5 ejection fraction
IRA 5 infarct-related artery
LV 5 left ventricular
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
rt-PA 5 recombinant tissue-type plasminogen
activator
TIMI 5 Thrombolysis in Myocardial Infarction trial
Figure 1. Schematic of trial design. ASA 5 aspirin; IV 5
intravenous; rt-PA 5 recombinant tissue-type plasminogen acti-
vator; TIMI 5 Thrombolysis in Myocardial Infarction trial.
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“planned rescue” angioplasty in rt-PA patients and “pri-
mary” angioplasty in placebo patients). If the IRA exhib-
ited normal (TIMI grade 3) flow, a second bolus of the
assigned study drug could be administered and PTCA
usually deferred. Left ventriculograms were then ob-
tained (right anterior oblique) with a radiopaque ball
filmed in the left axilla for calibration. Daily aspirin was
continued throughout the hospitalization, and IV heparin
was maintained for a minimum of 48 h (unless severe
bleeding occurred). Activated partial thromboplastin
times (aPTT) were drawn at randomization and every 6 h
for 48 h, with a target aPTT between 60 and 85 s (14).
Other drugs and technical approaches to mechanical
reperfusion were at the discretion of the investigators.
To assess for reocclusion and convalescent LV function,
follow-up angiography was repeated five to seven days later.
After four to six weeks, stress testing (exercise or pharma-
cological) was performed.
Enrolling facilities were experienced tertiary-care institu-
tions (Appendix B) providing rapid primary angioplasty
(except for one facility that transferred 10 patients to a
nearby partner tertiary-care hospital). Operators met AHA–
ACC (American Heart Association–American College of
Cardiology) experience guidelines (15). Sites were requested
to maintain screening logs of eligible AMI patients. Choices
of technical angioplasty approaches and supportive pharma-
cological therapies (other than study drug, aspirin, and
heparin) were at the discretion of the operators.
Adverse clinical events were defined as major bleeding (a
need for a transfusion $2 U of blood or intracerebral
bleeding), reocclusion, reinfarction, and death.
Angiographic core laboratory and coordinating center
procedures. The IRA was selected by core laboratory
angiographers, blinded to treatment, utilizing the elec-
trocardiogram, presence of arterial thrombus, and the
ventriculographic location of the contractile abnormality.
The IRA flow was judged on the initial contrast injec-
tion.
Ventriculographic silhouettes were acquired digitally at
end systole and diastole (borders defined by the core
laboratory angiographer). Cine projector output was linked
via an ITC RC Vision Plus frame grabber to an Image-
Comm StatVIEW workstation (Quinton Instrument,
Sunnyvale, California). Volumes and ejection fractions
(EFs) were calculated by the area-length method (16). The
infarct zone was further characterized by the most abnormal
50% of chords in an infarct region (the number of standard
deviations [SD] per chord), the number of consecutive
infarct zone chords .2 SD below the norm, and the
percentage of patients with no abnormal infarct zone cords
(17).
Sample size requirements. To detect an absolute differ-
ence of 10% between treatments in initial patency rates of
TIMI flow grade 3 with a power of 80% and } 5 0.05, a
total of 231 patients per group were required. This sample
size also allowed detection of a 20% difference in initial
patency rates of TIMI flow grades 2 and 3 with a power of
95% and } 5 0.05. To detect an absolute difference in
coronary reocclusion of 8% (6% vs. 14%) with a power of
90% and } 5 0.05, a total of 239 patients per group were
required. A sample of 142 patients per group is required to
detect an absolute difference of 5% in EF with a power of
90% and } 5 0.05. To account for patients without
follow-up angiography (anticipated to be 25%), the total
enrollment was set at 300 patients per group.
Statistical analysis. Continuous end points are expressed
as mean 6 SD unless otherwise noted. Chi-square tests
were used to compare frequencies of categorical variables.
Further pairwise comparisons were adjusted by the Bonfer-
onni method. Continuous end points of two groups were
compared by unpaired Student t tests; all p values are
two-tailed. The cumulative frequency distribution was ac-
complished by the Kaplan-Meier method. A p value #0.05
was indicative of significance. All analyses were performed
utilizing SAS software (SAS Institute, Cary, North Caro-
lina). No imputation methods were employed to account for
anticipated missing follow-up angiographic data.
RESULTS
No differences in baseline characteristics were found be-
tween the treatment groups (Table 1). Screening logs were
available from institutions enrolling 75% of study patients.
Sixty-three percent of patients meeting entry criteria at
these hospitals were enrolled. Reasons for not enrolling
Table 1. Baseline Characteristics
rt-PA
(n 5 302)
Placebo
(n 5 304)
Age (yrs) (mean, SD) 57.6 6 10.1 58.4 6 10.6
Height (cm) (mean, SD) 172.2 6 9.5 172.6 6 9.6
Weight (kg) (mean, SD) 83.5 6 15.8 83.5 6 17.6
Time to treatment (h) (pain
onset to 1st study drug)
median (25%, 75%)
2.3 (1.6, 3.3) 2.4 (1.8, 3.5)
Gender (% female) 20.9 21.7
Hypertension (%) 40.1 43.8
Current smoker (%) 43.7 43.8
History of smoking (%) 71.2 65.5
Previous PTCA (%) 5.3 6.6
History of CHF 1.0 0.3
Previous MI (%) 15.2 13.2
Diabetes (%) 15.9 16.8
% IDDM/DM 27.1 27.5
Family Hx of CAD (%) 49.2 49.5
Race (% white) 89.1 89.5
Killip at randomization (% $ 3) 1.7 1.0
Previous angina (%) 36.4 36.0
Hypercholesterolemia (%) 38.7 33.0
Anterior infarction (%) 36.0 37.4
Multivessel disease (%) 51.4 56.8
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were: physician preference (34.6%), patient refusal (18.4%),
competing myocardial infarction (MI) trial (11.4%), and
other (35.6%). No baseline characteristic differences were
noted between eligible patients enrolled versus those not
enrolled. Study drug kits were inadvertently opened prior to
recognition of study exclusion criteria for 10 patients who
were not enrolled: (2 patients age .75 years, 1 patient .6 h
from pain onset, 3 patients bleeding or stroke risk, 4 patients
other reasons).
For both treatment groups, patients arrived at the hospi-
tal at a median of 1.4 h following symptom onset. From
hospital arrival to study drug, a median of 49 min elapsed.
The median time from study drug to the initial IRA
contrast injection was also 49 min. No significant differences
were seen in any time interval by treatment group.
Among patients arriving at the cath lab, a patent artery
(TIMI flow grade 2 or 3) was seen approximately twice as
often in patients who received a thrombolytic than a placebo
(61% vs. 34%; p , 0.001). TIMI flow grade 3 was present
in 33% of rt-PA patients versus 15% of placebo patients
(p , 0.001) (Fig. 2).
The frequency distribution of time from study drug to
documenting TIMI flow grade 3 in patients who exhibited
this grade at the time of the first injection into the IRA
(without the need for angioplasty) and for patients with
lesser initial flow grades subsequently converted to TIMI
flow grade 3 by angioplasty is shown in Figure 3. The
difference of 42 min between the median time points was
significant (p , 0.0001).
No differences in angioplasty success between treatment
groups were evident (Table 2). Following rt-PA, conversion
of closed vessels (TIMI flow grades 0, 1) to patent vessels
(TIMI flow grade 2 or 3) was 92.8% and to TIMI flow
grade 3 alone, 76.6%; among placebo patients the values
were 94.6% and 79.0% (p 5 0.52 and 0.62, respectively).
When the initial flow was TIMI grade 2, angioplasty
restored the flow to grade 3 in 82.8% of rt-PA and 86.7% of
placebo patients (p 5 0.59). Among 116 patients with
TIMI flow grade 3 on catheter laboratory arrival and who
underwent follow-up angiography, 8 experienced reocclu-
sion (6/57 rt-PA, 2/26 placebo). In the 262 patients with
TIMI flow grade 3 restored by angioplasty and with
subsequent angiograms, 10 experienced reocclusion (5/101
rt-PA, 5/151 placebo).
Balloon angioplasty was the dominant intervention
(74%). Stenting was employed in 26% of patients in each
group and atherectomy devices in three patients. In addition to
protocol-required aspirin and heparin, abciximab was admin-
istered during the intervention to 5% of patients in each group.
LV function. Four hundred forty-four patients had an
analyzable initial left ventriculogram (73.3%; 220 rt-PA,
224 placebo). Three hundred seventy-three patients (61.6%;
182 rt-PA, 191 placebo) had a follow-up left ventriculogram
adequate for analysis. Missing or unanalyzable follow-up
studies are detailed in Table 3. Baseline characteristics
between patients with and without follow-up angiograms
were nonsignificant, except women less often received a
follow-up angiogram than did men (66.7% vs. 77.6%, p 5
0.01) and patients without a follow-up were slightly older
(60.1 years vs. 57.2 years, p 5 0.003).
Left ventricular function was analyzed by treatment
assignment and by method and timing of restored patency
(Table 4). The EF comparison by treatment assignment,
without regard for time, method of patency, or final flow
grade, was similar (58.2% vs. 58.4%, respectively, p 5 0.85).
Measures of regional infarct zone function parallel the EF
observations (Table 4).
Whereas treatment assignment did not influence ventric-
ular function, the timing of TIMI flow grade 3 restoration
did have a significant impact. Patients arriving at cath lab
with TIMI flow grade 3 IRA flow already established had
initial and convalescent EFs of 60.5% and 62.4% compared
with a later mechanical restoration (primary or planned
rescue PTCA) initial EF of 58.7% (p 5 0.26) and conva-
lescent EF of 57.9% (p 5 0.004). Never achieving TIMI
flow grade 3 (n 5 72) was associated with the lowest initial
EF (55.8%) and convalescent EF (54.7%).
Figure 2. Infarct-related artery patency at time of initial coronary
angiography. All treatment group comparisons p , 0.001.
Figure 3. Cumulative frequency distribution of time to TIMI flow
grade 3 in patients with (n 5 319) and without (n 5 141)
angioplasty at time of initial angiography. Patients with less than
TIMI flow grade 3 (n 5 133) are not included in the frequency
distributions.
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The small number of patients (n 5 25) in whom PTCA
restored TIMI flow grade 3 patency within 1 h of study
drug had a mean convalescent EF of 62.5%, not unlike those
who arrived in the catheter laboratory with already estab-
lished normal flow. In 88% (n 5 187) of mechanically
opened vessels, however, the procedure was accomplished
.1 h following study drug; these patients’ mean convales-
cent EF was 57.3%, significantly lower than in pharmaco-
logically reperfused and very early mechanically reperfused
patients (p , 0.005).
Adverse outcomes. No significant differences were ob-
served in any adverse event on the basis of treatment
assignment (Table 5). In rt-PA and placebo patients, the
incidence of major hemorrhage was 12.9% and 13.5%,
respectively (p 5 0.84). After excluding bleeding associated
with bypass surgery, the major bleeding rates were 8.5% and
8.2% for rt-PA and placebo, respectively (p 5 0.92). No
differences existed in bleeding rates between patients who
received two boluses of study drug versus those who received
one bolus. The need for later emergent revascularization was
7.3% in the rt-PA group and 7.2% in the placebo group
(p 5 0.98). Although not intended nor powered to be a
mortality trial, it is of interest that patients arriving in the
cath lab with an open IRA had a 30-day mortality rate of
2.1%; those requiring a PTCA to achieve TIMI flow grade
3, 3.1%, and those never achieving TIMI grade 3 flow, 4.7%
(p 5 0.48). At one year, the mortality rates were 2.8%,
5.3%, and 7.9% (p 5 0.18), respectively.
DISCUSSION
The advantages of thrombolytic therapy are universal avail-
ability and short time to administration. Its chief disadvan-
tage is the apparent limitation in restoring normal TIMI
grade 3 flow, generally reported to occur in not more than
60% to 65% of recipients within 90 min of therapy (18,19).
In contrast, primary PTCA has the advantage of higher
TIMI flow grade 3 rates, but its availability is more limited
and the delays prior to reperfusion can be substantial.
Because outcome after infarction is significantly determined
by the speed and degree of reperfusion restored and because
the advantages and disadvantages of the two approaches
appear complementary, it seemed logical to seek synergism
by designing a strategy that combined both treatments. The
results of PACT appear to confirm that such synergism can
be achieved despite a previously widely held opinion that
thrombolytics and angioplasty are not compatible.
Previous relevant studies. Interestingly, the evidence un-
derlying this opinion of noncompatibility was never partic-
ularly strong. One previous trial directly compared primary
PTCA with thrombolysis and immediate PTCA. O’Neill et
al. (6) performed angioplasty during an infusion of the
long-acting fibrinogen-depleting thrombolytic, streptoki-
nase, in 58 patients comparing their course with 63 primary
angioplasty patients. The success rate (TIMI flow grades 2
and 3) of PTCA in the combination treatment group was
98% versus 92% for primary PTCA. Follow-up LV function
showed a trend favoring the thrombolytic group. However,
an extraordinary incidence of bleeding and need for trans-
fusion (39%) occurred in the thrombolytic group, leading
the authors to voice caution regarding combination strate-
gies. The thrombolytic regimen selected in the present trial,
an initial bolus of 50 mg rt-PA, was chosen to take
advantage of its fibrinogen-sparing properties and extremely
short (4 to 5 min) half-life when administered as a bolus
with the goal of minimizing bleeding risk.
Other studies suggesting thrombolytic-angioplasty in-
compatibility include TIMI-IIA and IIB, TAMI-1 and 5
(Thrombolysis and Angioplasty in Myocardial Infarction),
and the European Cooperative Study Group (ECSG)
investigation (7–11). None of these actually compared a
Table 2. Technical Results of Angioplasty
Outcome rt-PA Placebo
p
Value
TIMI flow grades 0, 132,3 92.8% (103/111) 94.6% (176/186) 0.52
TIMI flow grades 0,133 76.6% (85/111) 79.0% (147/186) 0.62
TIMI flow grades 0,132 16.2% (18/111) 15.6% (29/186) 0.89
TIMI flow grades 233 82.8% (48/58) 86.7% (39/45) 0.59
Parentheses indicate actual patient numbers.
Table 3. Characteristics of Patients Without Follow-up
Catheterization
Characteristic Follow-up
No
Follow-up
Protocol follow-up performed 456 (75.2%) 150 (24.8%)
Follow-up performed but
technically not adequate
83 (13.7%)
Follow-up not performed due to
Patient refusal 36 (5.9%)
CABG before follow-up 33 (5.4%)
Physician preference 19 (3.1%)
Death 17 (2.8%)
Nonprotocol angiogram 17 (2.8%)
Patient too ill 8 (1.3%)
Early hospital discharge 4 (0.7%)
Unable to obtain vascular access 4 (0.7%)
Protocol error and other reasons 12 (2.0%)
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combined treatment approach versus traditional primary
angioplasty as done in the present trial. Rather, they studied
thrombolysis (all patients) followed by a conservative course
or by protocol-driven angiography and sometimes angio-
plasty. The interventions were more often delayed than
immediate, and most angioplasties were performed in an
already patent artery. Hence, they shed little light on the
value of thrombolysis with immediate rescue. Only three of
these studies performed interventions within the first 3 h
following onset of thrombolytic therapy and directed that
closed infarcts undergo PTCA attempts; such rescue pro-
cedures numbered 71 patients in the ECSG (11), 52 in
TAMI-5 (9), and 37 in TIMI-IIA (7). The PTCA success
rates were 80%, 89%, and 92%, respectively. The conclusion
by the ECSG was that early interventions provided no
benefit while augmenting risk (this study was prematurely
terminated after entering 367 patients). The TIMI-IIA
study, showed higher complication rates during acute inter-
vention compared with delayed intervention (18 to 48 h)
with no offsetting clinical benefits. In contrast, TAMI-5
suggested that early post-lytic intervention produced im-
proved outcome LV function and a better overall clinical
course than did conservative care. It should be noted that in
most of the above studies, thrombolytic infusions were
ongoing during the acute angioplasty procedures.
More recent specific-rescue PTCA reports have failed to
confirm increased complications, perhaps in part the con-
sequence of improved puncture site and sheath management
and revised adjunctive anticoagulation regimens (4,20,21).
The benefits of rescue angioplasty have been supported by
the one randomized trial of the issue and several reported
consecutive series (20–24).
The present trial has demonstrated that even a very
reduced dose of fibrin-selective plasminogen activator pro-
Table 4. Initial and Convalescent LV Function by Treatment Group and by Patency Grade
LV Function Parameter
rt-PA
(n 5 220)
Placebo
(n 5 224)
TIMI Flow Grade
3 on Catheter
Laboratory Arrival
(n 5 104)
TIMI Flow
Grade 3
After PTCA
(n 5 232)
Never TIMI
Flow Grade
3 (n 5 101)
Initial Outcome
Global EF 59.4% 6 13.8 57.7% 6 14.1 60.5% 6 14.6 58.7% 6 13.6 55.8% 6 13.4
Infarct zone SD/chord 22.53 6 1.33 22.69 6 1.30 22.14 6 1.37 22.73* 6 1.28 22.87 6 1.16
No. of pathological chords 20.4 6 16.9 23.3 6 18.3 16.0 6 16.3 23.6* 6 17.7 24.8 6 17.5
Follow-up outcome (n 5 182) (n 5 191) (n 5 85) (n 5 212) (n 5 72)
Global EF 58.2% 6 13.0 58.4% 6 12.5 62.4% 6 10.6 57.9%* 6 12.8 54.7% 6 13.7
Infarct zone SD/chord 22.19 6 1.41 22.25 6 1.38 21.74 6 1.48 22.31* 6 1.41 22.49 6 1.09
No. of pathological chords 16.9 6 16.6 17.9 6 16.4 11.5 6 13.5 18.2* 6 16.3 22.3 6 18.4
*Comparisons between TIMI flow grade 3 upon-arrival group vs. TIMI flow grade 3 after-PTCA group; p , 0.0002 for the initial study and p , 0.004 for the follow-up study.
There were no significant differences between the rt-PA vs. placebo groups. There were four fewer patients in the analysis by TIMI flow grade than in the treatment group analysis
owing to missing data in the former regarding method of recanalization. The comparable values for patients “Never TIMI Flow Grade 3” are provided for reference. Initial and
follow-up LV function data is included for 7 and 4 (respectively) study participants in whom IRA was undetermined.
Table 5. Adverse Outcomes
Outcome
rt-PA
(n 5 302)
Placebo
(n 5 304)
p
Value
Recurrent ischemia* 17.9% 13.5% 0.14
Reinfarction 3.0% 2.6% 0.80
Reocclusion† 5.9% (11/187) 3.7% (7/189) 0.32
Emergent 1st PTCA‡ 7.9% (8/101) 5.6% (3/54) 0.59
Emergent 2nd PTCA 4.6% (9/195) 2.1% (5/243) 0.13
Emergent CABG 2.0% 4.6% 0.07
Major hemorrhage§ 12.9% 13.5% 0.84
Major hemorrhage (excluding CABG
patients)
8.5% 8.2% 0.92
Any stroke 0.7% 0.7% 0.99
Intracerebral bleeding 0.3% 0.3% 0.99
In-hospital mortality 3.6% 3.0% 0.64
30-Day mortality 3.6% 3.3% 0.81
Ischemic ETT at 6 weeks 9.3% (19/205) 10.4% (21/202) 0.70
*Defined by clinical observation noted by the patient’s attending physician and care staff and recorded on the patient case report
form. †Angiographically defined reocclusion; subsequent angiogram must be present. ‡In patients whose TIMI flow grade 3 at
first angiogram precluded the need for angioplasty at that time. §Major hemorrhage is defined as intracerebral bleeding or the
need for $2 U of blood.
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duces an early patency advantage occurring before a me-
chanical reperfusion attempt can be initiated. Such very
early reperfusion is associated with improved outcome LV
function. When rescue angioplasty is nonetheless required,
there is no decrease in the procedure’s technical success rate
and no increase in adverse events. Thus, thrombolysis, as
employed in this trial, and angioplasty are compatible.
Time intervals. The absolute temporal advantage for pa-
tients arriving in the catheter laboratory with restored
complete patency can only be approximated as only the time
of such patency is initially recorded. Vessels open 51 min
after bolus treatment were likely open in advance of the first
documented picture. In contrast, the time of mechanical
flow restoration was precisely documented in the cath lab.
Hence, the 42-min difference noted in Figure 3 is likely to
be an underestimation. In a recent report by Liem et al.
(25), a 43-min “additional” delay was observed for patients
transferred to a tertiary-care hospital for primary angioplasty
compared with those presenting directly to the PTCA-
capable facility. Though not randomized, the apparent
penalty of this delay was larger infarct size by enzyme
analysis (LDH 1536 IU vs. 1235 IU, p , 0.005) and a
substantially lower follow-up EF six months after the MI
(43% vs. 47%, p , 0.003), findings quite confirmatory of
the observations in PACT and other reports (26–28).
Study limitations. The present study has design limita-
tions ascribable to prior concerns regarding safety (i.e.,
bleeding), regarding the effectiveness of PTCA when
performed with thrombolytics, and regarding an intent to
minimize the delays often encountered when primary
angioplasty is the selected treatment. Accordingly, the
dosing of rt-PA was purposefully conservative and the
trial performed in hospitals with remarkably short delays
from emergency department treatment to angioplasty.
One could speculate that a more aggressive thrombolytic
regimen would have increased the number of patients
with patency restored prior to catheter laboratory arrival.
It is also reasonable to speculate that thrombolysis
followed by angiography and planned-rescue PTCA
would be more advantageous in clinical environments
where delays from emergency department triage to
PTCA are longer than those observed in PACT. The
U.S. National Registry for Myocardial Infarction-2 re-
ports a 110-min delay to primary angioplasty for in-
hospital patients and 221 min for transferred patients
(29). It is likely that the longer the delay, the more
advantageous would have been the combination ap-
proach. Confirmatory studies with regimens tested in
more “real-world” environments would be of considerable
interest. The use of both stents and particularly glyco-
protein IIb/IIIa antagonists in this study was less fre-
quent than current practice, owing mainly to the recruit-
ment of most patients in advance of published results
with these approaches in ST elevation MI patients.
Implications. New strategies and therapies are scrutinized
not only for their benefits but also their costs. Proof of the
benefits of establishing earlier and more frequent reperfu-
sion has been amply provided in previous investigations
(19,30–32). Regarding the cost of applying two reperfusion
modalities to the same patient, some increase might be
offset by the immediate anatomic risk stratification pro-
vided, thereby obviating the need for other risk-stratifying
tests. Savings may also be accomplished in patients angio-
graphically identified as low risk by planning very early
hospital discharge (33). In the U.S., however, the biggest
cost-neutralizing factor is that more than 70% of
thrombolytic-treated patients undergo coronary angiogra-
phy during their initial hospitalization, with another 15% to
20% referred for angiography soon after the index hospital-
ization (34,35). Following the combined strategy studied in
PACT, the commonly performed angiogram is moved
forward in time so as to become a potentially therapeutic
(rescue) as well as diagnostic intervention.
Other pharmacological strategies intended to promote
IRA patency during the diagnosis-to-angioplasty delay have
been subject to previous and ongoing studies. Extraordinar-
ily high-dose unfractionated heparin initially appeared
promising, but the largest and most recent evaluation (36)
showed no difference in patency rates compared with standard
doses of heparin such as those used in the present investigation.
Patency rates following precatheter laboratory use of platelet
IIb/IIIa blockade are in an early stage of evaluation, and small
reports have produced variable observations (37).
The long-standing controversy between thrombolysis and
primary angioplasty may no longer be the most relevant
issue regarding the choice of reperfusion modalities for
AMI. A judicious use of both therapies in a comprehensive
combination treatment strategy is an attractive and possibly
preferable approach for a significant segment of the acute
infarct population, specifically those patients selected for
primary PTCA or stenting but in whom very rapid accom-
plishment of the planned procedure does not appear likely.
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APPENDIX B: PARTICIPATING INVESTIGATORS
United States (386 patients). George Washington Univer-
sity Hospital, Washington, DC: A. Ross, K. Coyne, P.
Walker, P. Verrier; Oakwood Hospital, Dearborn, MI: A.
Riba, C. Draus; Rochester General Hospital, Rochester, NY:
M. Thompson, V. Chiodo; Carolina Cardiology Associates,
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High Point, NC: S. Rohrbeck, T. Harrison; St. John’s
Hospital and Medical Center, Detroit, MI: T. Schreiber,
N. Malta; Oregon Cardiovascular Teachings, Eugene, OR:
L. Christie, Jr., M. Lind; Heart Center of Salt Lake, Salt
Lake City, UT: J. Perry, W. Schvaneveldt; Evanston Hospi-
tal, Evanston, IL: T. McDonough, B. J. Jackson; Hendrick
Medical Center, Abilene, TX: R. Harris, S. Hammond;
Cardiology Consultants, Spartanburg, SC: J. Story, M. Phil-
lips; Providence St. Vincent’s Medical Center, Portland, OR:
P. Block, B. Block; Glenbrook, Hospital, Evanston, IL:
T. McDonough, B. J. Jackson; Pepin Heart Center at
University Hospital, Tampa, FL: J. Smith, L. Harrah;
Swedish-American Hospital, Rockford, IL: R. Harner,
P. Kraus; Tulsa Regional Medical Center, Tulsa, OK:
E. Pickering, J. Durham; Piedmont Hospital, Atlanta, GA:
K. Rees, C. Thomas, L. Freschi, J. Stewart; St. Vincent’s
Medical Center, Jacksonville, FL: G. Pilcher, P. Zaenger;
Mother Frances Hospital, Tyler, TX: N. Israel, G. Murphy;
New York Hospital–Cornell Medical Center, New York, NY:
D. Altman, D. Silvasi; East Texas Medical Center, Tyler, TX:
N. Israel, D. Smith; Broward General Medical Center, Ft.
Lauderdale, FL: A. Neiderman, T. Kellerman; Gundersen
Lutheran Medical Center, La Crosse, WI: W. Brown,
D. Larson.
Canada (172 patients). Foothills Hospital, Calgary, Alberta:
M. Traboulsi, M. Knutdson, D. Galbraith; Hoˆpital Notre
Dame, Montre´al, Que´bec: N. Racine, L. Patry, D. Therrien;
Royal University Hospital, Saskatoon, Saskatchewan:
J. Lopez, P. Kuny; Vancouver Hospital and Health Sciences
Center, Vancouver, BC: A. Fung, C. Davies, H. Abbey; St.
Paul’s Hospital, Vancouver, BC: C. Thompson, E. Buller,
C. Li.
Argentina (28 patients). Sanatorio Mitre, Buenos Aires:
A. Sosa-Liprandi, M. I. Sosa-Liprandi, C. Sztejfman;
Instituto Cardiovascular de Rosario: R. Diaz, E. Paolasso,
M. Genisans; Clinica Bazterrica, Buenos Aires: J. Le-
guizamon; Hospital Santojanni, Buenos Aires: C. Tajer,
D. Ryba.
Germany (20 patients). Franz-Volharn-Klinik, Berlin:
D. Gulba; Lukas Krankenhaus, Neuss: W. Merx; Universta¨t
Ulm, Ulm: M. Kochs; University of Erlangen, Erlangen:
W. Moshage, R. Altstidl; George-August-Universta¨t, Go¨t-
tingen: H. R. Figulla; Elisabeth Krankenhaus, Essen:
B. Grosch.
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